文献速递系统性红斑狼疮

肌肉骨骼型系统性红斑狼疮临床与超声结局指标的反应度研究

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-03

该前瞻性预试验纳入20例有炎症性肌肉骨骼症状的SLE患者,在肌注120mg甲泼尼龙醋酸盐后0、2、4周评估SLEDAI、BILAG、关节计数、VAS及超声的反应度。结果显示BILAG和医生VAS反应度最高,超声高度敏感,而SLEDAI和关节计数对改善的检测欠佳,提示基于SLEDAI和SRI-4的临床试验可能低估疗效。

要点

  • BILAG和医生VAS是反应度最高的临床工具。
  • 超声在肌肉骨骼型SLE中反应度很高。
  • SLEDAI和关节计数对检测改善欠佳。

核心结论

  • BILAG和医生VAS是反应度最高的临床工具,超声高度敏感,SLEDAI和关节计数对改善检测欠佳。
  • 基于SLEDAI和SRI-4的临床试验可能低估SLE治疗疗效。

研究设计与样本

  • 前瞻性预试验,连续纳入20例有炎症性肌肉骨骼症状的SLE患者。
  • 在肌注120 mg甲泼尼龙醋酸盐后0、2、4周进行临床评估和超声检查。

主要发现

  • 肌肉骨骼BILAG评分在16/20例中改善,肌肉骨骼SLEDAI在7/20例中改善。
  • 基线SLEDAI≥4的19例中,第4周9/19例达到SRI-4标准。
  • 第4周效应量:超声、医生VAS和BILAG为大效应(>0.5),关节计数和SLEDAI为中等效应(>0.3)。
  • 第4周超声灰阶和能量多普勒在SRI-4应答者(r=-0.51和-0.56)和非应答者(r=-0.62和-0.59)中均显示大效应量改善。

关键数值与推荐

  • 效应量采用Cohen标准:大效应>0.5,中等效应>0.3。
  • SRI-4标准在基线SLEDAI≥4的19例中评估,第4周9/19例达到。

临床怎么用

  • 在肌肉骨骼型SLE的临床评估中,优先考虑BILAG和医生VAS以敏感反映改善。
  • 超声可作为客观炎症指标高度敏感地监测治疗反应。
  • 解读基于SLEDAI或SRI-4的试验结果时需注意其可能低估疗效。

局限性

  • 样本量小(20例),为预试验。
  • 原文未报告随访时间超过4周的数据。
  • 原文未报告盲法或对照设置等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the responsiveness of clinical outcome measures in musculoskeletal SLE compared with US. METHODS: A prospective pilot study was conducted in consecutive SLE patients with inflammatory musculoskeletal symptoms. Clinical assessments including SLEDAI, BILAG, 28 tender and swollen joint counts, physician and patient visual analogue scales (VAS), and US were performed at 0, 2 and 4 weeks following 120 mg i.m. methylprednisolone acetate. Responsiveness was analysed using changes and effect sizes using Cohen's criteria. RESULTS: Twenty patients were recruited. Fifteen out of 20 had clinical swelling at baseline. All clinical and US parameters were significantly improved at week 4 (all P ⩽ 0.01). Musculoskeletal-BILAG score improved in 16/20. Musculoskeletal-SLEDAI improved in 7/20. SLE responder index 4 criteria were assessed in 19 patients with SLEDAI ⩾4 at baseline and were met in 9/19 at 4 weeks. Effect sizes at 4 weeks were large (>0.5) for US, physician VAS and BILAG, and medium (>0.3) for joint counts and SLEDAI. Large effect sizes for improvement in US grey-scale and power Doppler were observed in both SLE responder index 4 responders (r = -0.51 and -0.56, respectively) and non-responders (r = -0.62 and -0.59, respectively) at 4 weeks. CONCLUSION: This is the first study to measure the responsiveness of clinical outcome measures in musculoskeletal SLE against an objective inflammation measure. BILAG and physician VAS were the most responsive clinical instruments. US was highly responsive in musculoskeletal SLE, while SLEDAI and joint counts appeared suboptimal for detection of improvement. These results suggest that clinical trials based on the SLEDAI and SLE responder index 4 may underestimate the efficacy of therapy in SLE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mahmoud K, Zayat AS, Yusof Y, et al. Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. Rheumatology (Oxford). 2019. PMID: 30608614. doi:10.1093/rheumatology/key422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。